Esperion Therapeutics, Inc. (ESPR)
NASDAQ: ESPR · Real-Time Price · USD
2.000
-0.030 (-1.48%)
At close: Nov 4, 2024, 4:00 PM
1.970
-0.030 (-1.50%)
Pre-market: Nov 5, 2024, 4:01 AM EST
Esperion Therapeutics Stock Forecast
Stock Price Forecast
The 3 analysts with 12-month price forecasts for ESPR stock have an average target of 8.17, with a low estimate of 2.50 and a high estimate of 16. The average target predicts an increase of 308.50% from the current stock price of 2.00.
Analyst Consensus: Buy
* Price targets were last updated on Oct 2, 2024.
Analyst Ratings
The average analyst rating for ESPR stock from 4 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | May '24 | Jun '24 | Jul '24 | Aug '24 | Sep '24 | Oct '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 2 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 1 | 1 | 1 | 1 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 4 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $16 | Strong Buy | Reiterates | $16 | +700.00% | Oct 2, 2024 |
| Needham | Needham | Strong Buy Maintains $8 → $6 | Strong Buy | Maintains | $8 → $6 | +200.00% | Aug 13, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $16 | Strong Buy | Reiterates | $16 | +700.00% | Aug 12, 2024 |
| Needham | Needham | Strong Buy Reiterates $8 | Strong Buy | Reiterates | $8 | +300.00% | Jun 28, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $16 | Strong Buy | Reiterates | $16 | +700.00% | Jun 28, 2024 |
Financial Forecast
Revenue This Year
348.54M
from 116.33M
Increased by 199.60%
Revenue Next Year
416.01M
from 348.54M
Increased by 19.36%
EPS This Year
-0.21
from -2.03
EPS Next Year
0.13
from -0.21
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 485.3M | 698.0M | 1.0B | ||
| Avg | 348.5M | 416.0M | 554.8M | ||
| Low | 301.0M | 239.8M | 344.4M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 317.2% | 100.3% | 142.1% | ||
| Avg | 199.6% | 19.4% | 33.4% | ||
| Low | 158.7% | -31.2% | -17.2% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 0.33 | 1.35 | 2.30 | ||
| Avg | -0.21 | 0.13 | 0.61 | ||
| Low | -0.44 | -0.47 | -0.36 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | 1,631.9% | ||
| Avg | - | - | 357.3% | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.